Norroy starts 600-patient Phase 3 trial of 177Lu-NYM032 in metastatic prostate cancer
Norroy Bioscience has started pivotal Phase 3 development of 177Lu-NYM032 in PSMA-positive metastatic castration-resistant prostate cancer, with a registered target enrollment of about 600 patients and overall survival as the primary objective.